Abstracts A65 sions included no evidence of a diabetes diagnosis prior to study intervals or death prior to the end of intervals. Indicated services based on ADA guidelines for lipid (LI) , retina examinations (RE), microalbuminuria (MA), serum creatinine (SC), influenza vaccinations (FV), and A1c tests were identified from CPT codes and HCPCS codes (≥ 2 annually for A1c tests and ≥1 annually for other tests). Logistic regression assessed associations between subprogram and assessments controlling for age, gender, ethnicity, comorbidity, and state region. RESULTS: A sample of 22,017 persons, with 57% FFS, 26% CM and 17% MC was identified. Overall, proportions (95% C.I.) meeting recommendations were
PDB59 TIME TO OPIOID USE AMONG COMMERCIALLY-INSURED PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN WHO INITIATED DULOXETINE VERSUS OTHER TREATMENTS
Zhao Y 1 , Chen SY 2 , Boulanger L 2 , Fraser K 2 , Wu N 2 1 Eli Lilly and Company, Indianapolis, IN, USA, 2 Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA OBJECTIVES: Opioids have commonly been used to treat chronic pain conditions, including diabetic peripheral neuropathic pain (DPNP), but tolerance issues have limited their use by providers. Newer classes of drugs are now approved for DPNP therapy, but no published data currently exists that assess changes in the utilization of opioid therapy following treatment with these newer agents. This study compared the use of opioids between DPNP patients who initiated treatment with duloxetine versus other standard of care (SOC) DPNP treatments. METHODS: This retrospective cohort study assessed commercially-insured DPNP patients aged 18 to 64 over a 1-year follow-up period who initiated treatment with either duloxetine or other SOC treatments (tricyclic, venlafaxine, gabapentin, pregabalin) between March 1,2005 and December 31, 2005 . Initiation was defined as a 90-day period without available study medication. Dispense date of the first study medication initiation was denoted as the index date. Selected patients had 12 months continuous enrollment before and after the index date, and no opioid pill coverage during the 90 days prior to initiation. Patients were matched to duloxetine-treated patients via propensity scoring, controlling for demographics, comorbidities, prior health care utilization and costs, and medication history. RESULTS: The matched sample included 117 patients in each of the duloxetine and SOC cohorts. Compared with SOC patients, duloxetine-treated patients were less likely to use any opioids (52.1% vs. 84.6%, p < 0.05) over the 12-month post-index period. Duloxetine-treated patients, on average, had 2 fewer opioid prescriptions dispensed, 27 fewer days on opioids, 120 days greater delay in subsequent opioid use, and 1816mg lower morphine equivalent dosage than SOC patients (all p < 0.05). Also, duloxetine-treated patients had significantly lower total ($18,623 vs. $30,602, p < 0.05) and outpatient costs ($7,371 vs. $15,343, p < 0.05). CONCLUSIONS: Duloxetine treatment is associated with deferred and reduced opioid use among DPNP patients. Patients initiated on duloxetine also had lower health care costs.
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GAPS IN MEDICAID COVERAGE AND THE RISK FOR HOSPITALIZATION AND MORTALITY AMONG INDIVIDUALS WITH DIABETES IN A MEDICAID PROGRAM
Yang Y, Banahan BF, Pace PF University of Mississippi, University, MS, USA OBJECTIVES: The objective of this study was to evaluate whether Medicaid coverage gap is associated with higher risks for diabetes-specific hospitalizations and all-cause mortality among working-aged adults (i.e., those aged 19-64 years) with diabetes. METHODS: Using administrative claims data, we conducted a retrospective cohort study of working-aged adults with diabetes and who were enrolled in a state Medicaid program. Coverage gap was defined as at least one month interruption in their Medicaid enrollment from January 2002 to December 2003. The primary outcomes of interest were diabetes-specific hospitalization and all-cause mortality during follow-up (January to December 2004). Multivariate regression analyses were performed to assess the independent association between adherence to statin and outcome measures. Key confounding variables include age, gender, race, comorbidities (measured using Charlson Comorbidity Index), prior hospitalization due to diabetes, and use of medications essential to diabetes management including oral hypoglycemic agents, insulin, antihypertensive agents, and statins. RESULTS: A total 24,996 patients were included in the study. Mean age 50.2 ± 10.3 years, 29.7% male, 70.3 female; 30.3% white, 59.3% black. About 86% had continuous Medicaid coverage and 14% had at least one month gap in their Medicaid coverage. During follow-up, those with at least one-month in their coverage were 16.2% less likely (OR: 0.838; 95%CI: 0.714-0.985) to have diabetes-specific hospital admissions and 44.9% less likely (OR: 0.551; 95%CI: 0.430-0.706) to have all-cause mortality during the follow up period. CON-CLUSIONS: The results from this study suggest that gaps in Medicaid coverage are not associated with higher risks for diabetes-specific hospitalizations and all-cause mortality in the follow up period. However, the study lacked information on why coverage gaps occurred and whether individuals with coverage gaps transitioned to other insurance coverage.
PDB61 RACIAL AND ETHNIC DISPARITIES IN QUALITY OF HEALTH CARE AMONG ADULTS WITH DIABETES IN THE UNITED STATES IN 2005 AND 2006
Zhang YJ 1 , Holiday-Goodman M 2 , Amialchuk A 2 , Jung R 2 full-year consolidated data files including the Diabetes Care Survey and the Self-Administered Questionnaire were combined and analyzed. The racial and ethnic disparities in receipt of recommended diabetes services (A1C test, foot exam, eye exam, lipid profile, and influenza immunization), timeliness, and patient centeredness were examined. Chi-square test and logistic regression were conducted to evaluate the disparities before and after controlling for the confounding factors (age, gender, family income, education, health insurance coverage, residential location, and language spoken most often at home). RESULTS: In 2005-2006, the racial and ethnic disparities in quality of health care among U.S. adults with diabetes still exist even after controlling for demographic and socioeconomic factors. African Americans and Hispanics were less likely to receive recommended diabetes services and patient-centered health care than Whites. African Americans had more foot examinations than Whites and Hispanics. There was no significant difference in timeliness of health care among racial and ethnic groups. CONCLUSIONS: Racial and ethnic disparities in receipt of recommended diabetes services and patient centeredness of health care among adults with diabetes remained in the U.S. in [2005] [2006] . Age, family income, health insurance coverage, education, residential location, and English-speaking were correlated with racial and ethnic disparities. As this study is focused on disparities among only Whites, African Americans, and Hispanics, future studies comparing possible differences among other U.S. ethnic groups (e.g., American Indians or Alaska Natives) are needed using more-year, larger databases.
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EFFECTS OF HEALTH INSURANCE PLAN TYPE ON HEALTH CARE RESOURCE UTILIZATION IN ADULT WORKING AGE PATIENTS WITH TYPE 2 DIABETES MELLITUS
Kirk JR 1 , Campbell C 1 , Vivian F 1 , Zhao Y 1 , Olukotun AY 2 , Shi L 1 1 Tulane University, New Orleans, LA, USA, 2 CarioVax, LLC, Princeton, NJ, USA OBJECTIVES: The objective of this study was to evaluate the main effect of health insurance plan type on health resource utilization (emergency room (ER) visit or hospital admission) in privately insured patients with Type 2 diabetes between the ages of 18 to 64 years. The outcomes of interest were the odds of an emergency room visit or a hospital admission associated in patients with Type 2 diabetes. METHODS: The data source was the 2000-2001 MarketScan database, which is comprised of administrative claims data for over 2.5 million privately insured individuals in the United States. The odds of an emergency room visit or hospital admission were evaluated using multiple logistic regression models specified to control for demographic and clinical characteristics of the target patient population. A propensity score analysis using the stratification approach was also done to further control for selection bias. RESULTS: After adjusting for the covariates, patients enrolled in FFS plans were significantly more likely to experience an ER visit or an inpatient stay compared to patients in capitated plans (odds ratio for ER visit: 1.64, p < 0.05; odds ratio for an inpatient stay: 1.11, p < 0.05). CONCLUSIONS: The results of this study confirm that utilization rates are higher in FFS plans; however, the strength of the association was not as robust when the regression models were adjusted for propensity score. Capitated plans seek to reduce resource utilization.
PDB63 COMPARATIVE RESULTS ON EFFECTS OF TYPES OF INSURANCE AND PAYMENT PLANS ON PHYSICIANS'COST AWARENESS DURING THE PHYSICIAN VISIT USING THE NAMCS SURVEY IN 1996 AND 2005
Huttin C 1 , Wong D 2 1 ENDEPUSresearch , Inc and University Aix Marseille III, Cambridge, MA, USA, 2 ENDEPUSresearch,Inc, Cambridge, MA, USA OBJECTIVES: This paper compares physician's cost awareness of types of payments and insurance status at the point of visit, using two analytical datasets extracted from the National Ambulatory Medical Care survey (NAMCS) on patients diagnosed with Type II diabetes without complications. It analyzes the effects of various changes in the physician survey. METHODS: Two analytical datasets are constructed for diabetic patients Type II with no complication identified with code 25.00, one of 694 individuals in 1996 and one of 620 for 2005. Pharmacological treatment has been defined by building two drug lists for 1995/1996/1997 and 2004-2005-2006 from Facts and Comparisons books (one year before -one year after the year of reference) and the Brixner et als study (2008) . Drug codes used for the two periods are generic codes. The coding has been revised in order to integrate the withdrawal of FDA codes and the transition to new Multum drug classification system. A disease economic model is used. Dependent variables represent access and use of drug therapy. RESULTS: Drug codes for the two references periods substantially differ. New development of the disease model are described between 1996 and 2005 to integrate these drug codes changes,the introduction of electronic records, new types of financial information, new benefit designs and changes of clinical guidelines. It transforms the previous series of cross sectional modeling tested on 3 chronic conditions into a time series and dynamic framework. The model describes prescribing patterns of new versus old classes (especially TZD and new insulin analogs), evolution of modes of administration and impact of electronic records. CONCLUSIONS: The paper contributes to show the interest of disease modeling not only by medical schools but also with an economic perspective. Even after triages from health care administrators for categorization of patients into various health plans, physicians are cost aware at the time of visit and this influences their prescribing decisions.
PDB64 USING DECISION MODELING TO DETERMINE COST-EFFECTIVENESS OF PHARMACIST INTERVENTIONS FOR PATIENTS WITH DIABETES
Pinto S, Holl S University of Toledo, Toledo, OH, USA OBJECTIVES: Prevention or mediation of adverse events can significantly impact a patient's quality of life and their employer's health care costs. Decision modeling can be utilized to map pharmacists interventions provided through an employee-sponsored medication therapy management (MTM) program and calculate consequent cost savings associated with improved clinical outcomes. METHODS: A total of 700 employees from 2 employer groups participate in a pharmacist provided MTM program. A team of clinicians and researchers classified and created codes for specific pharmacist interventions, resultant physician and/or patient responses, and consequent outcomes. Data was extracted from patient charts and entered into Microsoft Excel. Costs associated with each decision outcome were calculated from claims data. A one-year decision-analytic model was constructed using TreeAge Pro Suite 2008 to identify the cost savings per intervention. RESULTS: A total of 218 interventions were made by the pharmacists. The most frequently used interventions were "explained and advised the use of pattern management" (N = 95, 43.4%) and "alerted the physician of an abnormal A1c level" (N = 64, 29.2%). Cost savings resulting from diabetic interventions for ER visits ($71.00 -$337 PPPY), inpatient hospitalization ($460.00 -$2360.00 PPPY), and total costs ($26.00 -$274.00 PPPY). All but one intervention resulted in a loss of cost savings for office visits, indicating that patients visited specialty physicians more often after beginning the program. The total cost savings for these interventions were $165.00 PPPY and $145.00 PPPY, respectively. CONCLU-SIONS: This decision-analytic model can be used as a rubric for providers seeking the most effective interventions to utilize for MTM programs, thereby reducing trial-anderror and diminishing health care costs. The model illustrates the potential return on investment the employer realized as a result of sponsoring employee participation in this program.
PDB65 IMPROVED PATIENT OUTCOMES RESULTING FROM PHYSICIANS' THERAPY DECISIONS BASED ON PHARMACISTS' RECOMMENDATIONS
Pinto S, Blazejewski L, Holl S University of Toledo, Toledo, OH, USA OBJECTIVES: Literature suggests that while pharmacists may be viewed as the most trusted health care professionals by patients, other health care professionals may often fail to trust them with making decisions regarding drug therapy regimens. Limited information is available regarding physicians' therapy decisions based on pharmacist's recommendations and the resulting patient clinical outcomes. This study aimed at finding if physicians' therapy decisions based on pharmacist's recommenda-tions lead to optimal patient outcomes. METHODS: Approximately 700 employees from 2 employer groups have participated in an employer-supported pharmacist provided disease state management program. The program is provided at seven independent pharmacies across Northwest Ohio. A team of clinical pharmacists and researchers classified and created codes for specific pharmacist-provided interventions, resultant physician and/or patient responses, and consequent outcomes. Data was extracted from patient charts and entered into Microsoft Excel. Frequencies and percentages of pharmacists' interventions, physicians' responses and outcomes were calculated using SPSS ver. 17.0. A decision tree was created using TreeAge Pro Suite 2008 to map interventions to responses to improved/unimproved outcomes. RESULTS: A total of 446 pharmacist interventions with corresponding physician responses and patient outcomes were made. The most frequent interventions involved drug therapy (N = 138, 31%) and formulary management (N = 105, 23.5%). The most frequent responses by physicians were "physician acknowledged recommendation, monitoring added" (N = 58, 13%) and "physician added a medication" (N = 51, 11.4%). Physicians responded favorably to the pharmacists' interventions 54.1% of the time. When physicians responded favorably, an improvement was seen in 91.2% of patient outcomes compared to only 64% when physicians declined or did not respond to pharmacists' interventions. CONCLUSIONS: Positive health outcomes result from therapy decisions made by physicians following pharmacists' recommendations. In an effort to save costs and improve care, pharmacist-physician collaboration is essential. and (c) retinopathy. Variables such as demographic, clinical, pharmacy, and medical utilization patterns along with medication adherence were also reported. RESULTS: A total of 287,195 patients with diabetes were identified, with 92% of the patients identified as having type 2 diabetes. Mean age of the patients was 53 years, and 52% were male. Over 70% of the patients with diabetes had cardiovascular risk factors such as hypertension; 4%, 13%, and 11% of the diabetes population had nephropathy, neuropathy, and retinopathy, respectively. Sixty-seven percent of the diabetes patients received HbA1c testing, while 71% of the patients received LDL-C screening within one year. Testing within one year was less than the national HEDIS Medicaid 25th percentile level (74.4%) for HbA1c and greater for LDL-C screening (66.9%). The RADAR tool effectively evaluated the selected HEDIS comprehensive diabetes care measures in the i3 Innovus database. CONCLUSIONS: In this population, LDL-C screenings within one year for diabetes patients were above the national HEDIS lowperformance level, while HbA1c testing within one year for diabetes patients was below the low-performance level, utilizing the RADAR tool for analyses. These findings indicate an opportunity for improvement.
PDB66 EVALUATION OF SELECTED COMPREHENSIVE DIABETES CARE MEASURES IN A MANAGED CARE DATABASE BY USING THE RETROSPECTIVE ANALYSIS FOR DIABETES ACTION AND REPORTING TOOL
PDB67 ECONOMIC EVALUATION OF TYPE 2 DIABETES -IMPACT OF PRICING AND REIMBURSEMENT REFORMS
Ilavska A 1 , Glatz P 2 , Hloska A 3 , Filko M 4 1 Medispektrum, Bratislava, Slovak Republic, 2 Janssen-Cilag, Bratislava, Slovak Republic, 3 Ministry of Health, Bratislava, Slovak Republic, 4 Ministry of Finance, Bratislava, Slovak Republic OBJECTIVES: Type 2 diabetes mellitus is serious condition associated of chronic complications whose economic impact on both patients and society is constantly increasing. Diabetics are the 4st in the drug spending in Slovakia. Our objectives was to explore drug costs for diabetes and besides the costs to explore also drug consumption and number treated patients with antidiabetics. METHODS: The data on drugs consumption were from national databases IMS Health and Pharmadata Ltd. with 293.935 diabetic patients cohort data in 4 years. To look into the impact of the drug policies in the Slovak Republic in 2006-2009. We calculated the impact of several regulatory measures on the size of the market and health insurance expenditure. Among the evaluated measures were: a) Lowering the VAT for drugs from 19% to 10%, effective from 2007 b) flat price cut in 2007 (-6.6%) and in 2008 (-7.4%) c) introduction of degressive mark-up for wholesalers and for pharmacies d) first and second rounds of the international reference pricing for all drugs in 2009. RESULTS: The total antidiabetics volume (oral antidiabetics + insulin) of the Slovak market in 2009 was °38.9 mil in manufacturers´ prices. 5% of the population with type 2 diabetes accounted for 8% of the total health care expenditure in Slovakia. In 2006 to 2009 number of treated patients with antidiabetics increased by 11%. In 2006 to 2009 7 new antidiabetics (molecules) entered the market. The regression results (40.0 vs °38.9 mil) suggested a positive relationship between the reimbursement price and
